Back to search

Article

Genetic Evidence for a Novel Glutamatergic Augmentation in Treatment-Resistant OCD: CREB1 as a Key Driver of Impaired Plasticity

2025-12-24

Abstract excerpt

<h4>Background: </h4> A large proportion of people with obsessive–compulsive disorder (OCD) – roughly 40–60 % even after carefully optimised treatment – do not improve enough with selective serotonin re-uptake inhibitors (SSRIs). Small naturalistic series have suggested that the Cheung Glutamatergic Regimen (CGR), an inexpensive oral combination of dextromethorphan, fluoxetine and piracetam, can ease symptoms quic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c8d22205-d3f1-51fb-b796-f27ae71b3632
DOI
10.20944/preprints202512.2104.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Genetic Evidence for a Novel Glutamatergic Augmentation in Treatment-Resistant OCD: CREB1 as a Key Driver of Impaired PlasticityDOI 10.20944/preprints202512.2104.v1
Select a neighboring publication to make it the new centre.